| XIRP2 altered in cohorts of …ALTERED_INderived22 of 22show fewer |
|---|
| → altered in cohorts of | Skin Squamous Cell Carcinoma 28 / 39 cases (72 %) · ssm · cscc_hgsc_bcm_2014 | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Skin Basal Cell Carcinoma 74 / 126 cases (59 %) · ssm · bcc_unige_2016 | — | — | Skin Basal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cutaneous Melanoma 151 / 469 cases (32 %) · ssm · skcm_tcga_gdc · largest of 7 cohorts | — | — | Cutaneous Melanoma | 7 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Adenocarcinoma 150 / 566 cases (27 %) · ssm · luad_tcga_pan_can_atlas_2018 · largest of 8 cohorts | — | — | Lung Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| → altered in cohorts of | Melanoma 37 / 144 cases (26 %) · ssm · mel_dfci_2019 · largest of 2 cohorts | — | — | Melanoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Non-Small Cell Carcinoma 268 / 1,144 cases (23 %) · ssm · nsclc_tcga_broad_2016 · largest of 2 cohorts | — | — | Lung Non-Small Cell Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Squamous Cell Carcinoma 95 / 484 cases (20 %) · ssm · lusc_tcga_gdc · largest of 5 cohorts | — | — | Lung Squamous Cell Carcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Small Cell Carcinoma 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Carcinoma 81 / 517 cases (16 %) · ssm · ucec_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Endometrial Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Renal Cell Carcinoma 24 / 158 cases (15 %) · ssm · rcc_iatlas_immotion150_2018 | — | — | Renal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastroesophageal Junction Adenocarcinoma 66 / 518 cases (13 %) · ssm · stes_tcga_pub | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Esophageal Adenocarcinoma 23 / 185 cases (12 %) · ssm · esca_tcga | — | — | Esophageal Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Endometrioid Adenocarcinoma 30 / 247 cases (12 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colon Adenocarcinoma 50 / 429 cases (12 %) · ssm · coad_tcga_gdc · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastric Adenocarcinoma 52 / 478 cases (11 %) · ssm · stad_tcga · largest of 4 cohorts | — | — | Gastric Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Head and Neck Squamous Cell Carcinoma 52 / 515 cases (10 %) · ssm · hnsc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Head and Neck Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Bladder Urothelial Carcinoma 40 / 474 cases (8.4 %) · ssm · blca_msk_tcga_2020 · largest of 5 cohorts | — | — | Bladder Urothelial Carcinoma | 5 | Observed | cbioportal | graph → |
| → altered in cohorts of | Hepatocellular Carcinoma 41 / 494 cases (8.3 %) · ssm · hcc_clca_2024 · largest of 4 cohorts | — | — | Hepatocellular Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colorectal Adenocarcinoma 70 / 1,015 cases (6.9 %) · ssm · crc_sysucc_2022 · largest of 2 cohorts | — | — | Colorectal Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Clear Cell Renal Cell Carcinoma 28 / 451 cases (6.2 %) · ssm · kirc_tcga | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Glioma 24 / 444 cases (5.4 %) · ssm · difg_glass_2019 | — | — | Diffuse Glioma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | B-Cell Non-Hodgkin Lymphoma 40 / 755 cases (5.3 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |